Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Theravance Biopharma's Days Payable or its related term are showing as below:
During the past 13 years, Theravance Biopharma's highest Days Payable was 3816.42. The lowest was 231.74. And the median was 1295.09.
TBPH's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.1 * Ranked among companies with meaningful Days Payable only.
Theravance Biopharma's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Theravance Biopharma Days Payable Related Terms
Theravance Biopharma Days Payable Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Theravance Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Theravance Biopharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theravance Biopharma (TBPH) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Theravance Biopharma and its competitors. Over the past decade, Theravance Biopharma's Days Payable has ranged from 231.74 to 3,816.42. According to the industry distribution chart, Theravance Biopharma ranks #999999 out of 702 companies in the Biotechnology industry.
Is Theravance Biopharma's Days Payable too high?
Theravance Biopharma's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 231.74 to a high of 3,816.42. Based on the distribution chart, Theravance Biopharma ranks #999999 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's Days Payable compare to ABUS and SANA?
According to the Biotechnology industry distribution chart, Theravance Biopharma ranks #999999 out of 702 companies for Days Payable. This places Theravance Biopharma in the lower half of its industry. The industry median Days Payable is 113.10. Historically, Theravance Biopharma's own Days Payable has ranged from 231.74 to 3,816.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Theravance Biopharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theravance Biopharma's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (TBPH) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.67, compared to a current price of $16.86 — trading 9.7% below its estimated fair value. The current Days Payable is 0.00. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Theravance Biopharma (TBPH), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (TBPH) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of $16.86 is trading 9.7% below its estimated GF Value™ of $18.67.
GuruFocus considers Theravance Biopharma to be Modestly Undervalued.
Key valuation signals for TBPH:
Days Payable: 0.00
GF Value™: $18.67 vs. price of $16.86 (9.7% below fair value)
No single metric tells the full story. See the TBPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for TBPH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TBPH has been successfully added to your 
